Apellis Pharmaceuticals announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, M.D., Ph.D., who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy. Dr. Baumal serves as a professor of ophthalmology at New England Eye Center, Tufts Medical Center, specializing in diseases and surgery of the retina and vitreous.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
- Vaxcyte named as Top Pick, added to Conviction list at Needham
- Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Wells Fargo downgrades Apellis to Equal Weight, lowers price target to $58
- Apellis downgraded to Equal Weight from Overweight at Wells Fargo